Business Insights' The Top 10 Generic Pharmaceutical Companies

The top 10 generics companies accounted for 28.5% of the global market in 2007. Leading players are actively updating their product portfolios and seeking growth opportunities in emerging markets.

The global generics market grew at a faster pace than the global pharma market in 2007, with a CAGR of 16.4% during 2004–2007. However, the generics market is changing due to the threat from authorized generics, competition from players in emerging countries and increasing consolidation. Teva's acquisition of Barr Pharmaceuticals is the latest example of companies attempting to improve their market strength and geographical reach via divestments and acquisitions.

Business Insights' special report The Top 10 Generic Pharmaceutical Companies: Positioning, Performance and SWOT Analyses analyzes the size, structure, and competitive landscape of the global generics market. The top 10 generics companies are assessed based on their market shares, product performances, therapeutic focus and future outlook, and the key issues and challenges facing these companies are examined.

Click here to view the eight-page executive summary of this report.

The latest industrial trends and developments are assessed across the generics markets of the UK, France, Germany, Italy, Spain and the US. This report also evaluates the strengths and weaknesses of the leading players and provides insights into the opportunities and threats that face them.

Use this new report as a platform to:

• Benchmark the top 10 generic companies over the 2004-07 period, and use detailed company analysis to measure the performances and outlooks of major players including Novartis, Teva, Mylan, Apotex, Ratiopharm, Pfizer, Sanofi-Aventis, Watson, Bayer and Stada.
• Assess the market dynamics, sales volumes and growth drivers of major generics markets with this report’s analysis of countries including the UK, France, Germany, Italy, Spain and the US.
• Evaluate the strategies of leading generics companies by using this report to measure the success of their currently marketed products and identifying their geographic expansion, product innovation tactics, major acquisitions/divestments and new product launches.
• Identify the therapeutic focus of the top 10 generics companies, understand how company product portfolios are evolving and examine future growth opportunities within key therapeutic areas.
• Measure the industrial impact of the latest trends and issues including the implications of patent expirations and the future potential of emerging generics markets such as Brazil, Russia, India and China.

Click here to view the eight-page executive summary of this report.